Gankyrin drives malignant transformation of chronic liver damage-mediated fibrosis via the Rac1/JNK pathway

X Zhao1,2,6, J Fu2,3,6, A Xu2, L Yu2,3, J Zhu2, R Dai2, B Su2, T Luo2, N Li2, W Qin2, B Wang2, J Jiang2, S Li4, Y Chen*2,3 and H Wang*1,2,3,5

Hepatocarcinogenesis is a complex process involving chronic liver injury, inflammation, unregulated wound healing, subsequent fibrosis and carcinogenesis. To decipher the molecular mechanism underlying transition from chronic liver injury to dysplasia, we investigated the oncogenic role of gankyrin (PSMD10 or p28GANK) during malignant transformation in a transgenic mouse model. Here, we find that gankyrin increased in patients with cirrhosis. In addition to more severe liver fibrosis and tumorogenesis after DEN plus CCl4 treatment, hepatocyte-specific gankyrin-overexpressing mice (gankyrinhep) exhibited malignant transformation from liver fibrosis to tumors even under single CCl4 administration, whereas wild-type mice merely experienced fibrosis. Consistently, enhanced hepatic injury, severe inflammation and strengthened compensatory proliferation occurred in gankyrinhep mice during CCl4 performance. This correlated with augmented expressions of cell cycle-related genes and abnormal activation of Rac1/c-jun N-terminal kinase (JNK). Pharmacological inhibition of the Rac1/JNK pathway attenuated hepatic fibrosis and prevented CCl4-induced carcinogenesis in gankyrinhep mice. Together, these findings suggest that gankyrin promotes liver fibrosis/cirrhosis progression into hepatocarcinoma relying on a persistent liver injury and inflammatory microenvironment. Blockade of Rac1/JNK activation impeded gankyrin-mediated hepatocytic malignant transformation, indicating the combined inhibition of gankyrin and Rac1/JNK as a potential prevention mechanism for cirrhosis transition.

Cell Death and Disease (2015) 6, e1751; doi:10.1038/cddis.2015.120; published online 7 May 2015

Hepatocellular carcinoma (HCC) is the prototype of inflammation-associated cancer, as most patients with HCC have an established background of unresolved chronic liver disease and cirrhosis. Major HCC risk factors include infection with hepatitis viruses, intake of aflatoxin-contaminated food, alcoholic liver disease, nonalcoholic steatohepatitis (NASH), chronic hepatic inflammation and cirrhosis. Cirrhosis is the primary risk factor for developing HCC, accompanied by long periods of chronic liver disease. However, the molecular mechanisms of this malignant transformation remain elusive.

Gankyrin was identified as an oncoprotein that frequently overexpressed in human liver cancers and increased in the earlier stage of liver carcinogenesis. It controls phosphorylated Rb and p53 degradation, promotes the expansion of tumor-initiating cells and accelerates HCC progression. In addition, it has also been shown to regulate NF-κB and AKT. We recently found that, in a rat model of carcinogen-induced liver carcinogenesis, gankyrin elevated in the stage of cirrhosis. However, it is still unknown how gankyrin promotes hepatocarcinogenesis in vivo.

Here, we show increased gankyrin expression in patients with cirrhosis. We further used hepatocyte-specific gankyrin-overexpressing mice to study the role of gankyrin in hepatocarcinogenesis. Sustained gankyrin activation promotes DEN plus carbon tetrachloride (CCl4)-induced HCC formation. Moreover, it aggravates CCl4-mediated liver injury, hepatic fibrosis and ultimately leads to the development of cirrhosis and progression into HCC.

Results

Gankyrin accelerates hepatocarcinogenesis in livers with chronic damage and fibrosis. Most patients with HCC have liver cirrhosis, which develops for long periods of chronic liver disease. Here, we observed elevated expression of gankyrin in clinical cirrhosis biopsies (Supplementary Figure S1), consistent with our previous studies that gankyrin gradually increased during DEN-induced liver cirrhosis and HCC in rat. Increased expression of gankyrin in human HCC correlated with poor survival and disease recurrence after surgery.

Acknowledgments

These authors contributed equally to this work.

Abbreviations: HCC, hepatocellular carcinoma; CCl4, carbon tetrachloride; DEN, diethylnitrosamine; CK7, cytokeratin-7; AFP, alpha fetoprotein; JNK, c-jun N-terminal kinase; α-SMA, α-smooth muscle actin; TUNEL, terminal-deoxynucleotidyl transferase-mediated nick end labeling; PCNA, proliferating cell nuclear antigen; ALT, alanine transaminase; AST, aspartate transaminase; HSC, hepatic stellate cell

Received 19.12.14; revised 17.3.15; accepted 24.3.15; Edited by M Agostini
contribution of gankyrin to hepatocarcinogenesis in vivo, we constructed a new transgenic mouse strain gankyrin<sup>hep</sup>, in which a human gankyrin protein expresses specifically in the hepatocytes driven by the albumin promoter. To examine the efficiency of gankyrin overexpression in the liver, we measured gankyrin expression in four different transgenic lines with RT-PCR and western blot assay. As shown in Figure 1a, the expression efficiency of gankyrin was variable in different lines, and thus we chose lines 2# and 4# for breeding and for further use. We subjected transgenic mice and littermates to a combination of DEN and the hepatotoxin CCl<sub>4</sub> for 6 months. This model shares typical features of the majority of human HCC development, and it faithfully recapitulates the natural history of chronic injury, inflammation and fibrosis. Gankyrin<sup>hep</sup> mice displayed a profound augment of tumor number, the largest size and hepatic fibrosis after DEN plus CCl<sub>4</sub> injections (Figures 1b and c). Moreover, in the wild-type mice treated with DEN and CCl<sub>4</sub>, the endogenous gankyrin expression increased significantly (Figure 1d). Thus, we proposed that gankyrin

Figure 1  Gankyrin accelerates hepatocarcinogenesis in chronically injured liver. (a) Construct design of generating hepatocyte-specific gankyrin transgenic mice. Genotype of mice was determined by PCR, and expression levels of gankyrin in four different transgenic lines were examined by RT-PCR and western blot assay, normalized to GAPDH. (b) Macroscopic liver appearance of gankyrin<sup>hep</sup> mice and littermates injected with DEN+CCl<sub>4</sub> for different durations. Tumor number and the largest size were quantified (n = 6). (c) Liver sections from b were collected for Sirius red staining (×100). (d) Representative photographs and H&E staining (original magnification ×100 and ×400) of livers from 16-week CCl<sub>4</sub>-treated gankyrin<sup>hep</sup> mice (n = 10) and control littermates (n = 8). Tumor incidence was determined. (e) Immunohistochemical staining of CK7 and AFP in tumor area. (f) Sirius red staining of liver sections from d (×100) and quantified with the ImageJ software. Data are represented as mean ± S.D. *P < 0.05; **P < 0.01. Scale bar, 100 μm
accelerates chronic liver injury-induced hepatocarcinogenesis.

To further study whether gankyrin-directed tumorigenesis is associated with chronic hepatic injury, inflammation and fibrosis, a model of long-term CCl₄ administration was used. We treated gankyrin<sub>hep</sub> mice and control littermates with persistent CCl₄ injection for 16 weeks. Expression of CYP2E1 was similar in liver tissues from control and gankyrin<sub>hep</sub> mice, suggesting no difference between the two groups on CCl₄ metabolism (Supplementary Figure S3). As illustrated in Figure 1e, nearly 50% of gankyrin<sub>hep</sub> mice had developed single or multiple surface nodular tumors after 16 weeks of CCl₄ treatment, whereas no nodules were observed in the surface of livers in the wild-type littermates. Histologic analysis revealed the occurrence of hepatocarcinoma only in gankyrin<sub>hep</sub> mice (Figure 1e). Immunostaining with anti-alpha fetoprotein (AFP) antibody confirmed that the tumors of gankyrin<sub>hep</sub> mice definitely originated from the hepatocytes. By contrast, no staining of CK7 was detected in the tumors (Figure 1f). Consistently, Sirius red staining showed more severe liver fibrosis in gankyrin<sub>hep</sub> mice (Figure 1g). Thus, it suggests that gankyrin-induced hepatocarcinogenesis is associated with chronic liver injury and fibrosis.

**Gankyrin in hepatocytes enhances CCl₄-mediated liver fibrosis.** Owing to a causal relationship between chronic injury, inflammation and hepatocarcinogenesis in most patients with HCC, the role of gankyrin during this process remains unknown. As presented in Supplementary Figure S4, after 2-, 4- and 8-week CCl₄ treatments, gankyrin<sub>hep</sub> mice had accelerated hepatic fibrosis, as evidenced by higher Sirius red staining. Consistently, real-time PCR analysis also confirmed higher expression of liver fibrosis-related genes TGF-β1, collagen-1 and TIMP1 in the liver from gankyrin<sub>hep</sub> mice than that from littermates (Figure 2a). Given that hepatic stellate cells (HSCs) have a critical role in inducing fibrosis, we measured the levels of α-smooth muscle actin (α-SMA) and desmin proteins. As shown in Figures 2b–d, more α-SMA and desmin were displayed in the gankyrin group after CCl₄ treatment. These results thereby demonstrated the importance of gankyrin in accelerating CCl₄-mediated chronic liver fibrosis.

**Gankyrin augments CCl₄-mediated chronic hepatic injury, inflammation and compensatory proliferation.** To reveal the basis for the increased susceptibility of gankyrin<sub>hep</sub> mice to chemical carcinogenesis, we explored early effects of CCl₄ on cell behavior and signal transduction. Higher levels of serum alanine transaminase (ALT) and aspartate transaminase (AST) indicate accelerated hepatocellular damage in gankyrin<sub>hep</sub> mice (Figure 3a). As expected, morphologic analysis showed more abnormal architecture in gankyrin<sub>hep</sub> mice relative to littermates after CCl₄ treatment (Figure 3b). Moreover, more severe inflammatory response was observed in gankyrin<sub>hep</sub> mice, as evidenced by higher serum levels of TNF-α or IL-6 and enhanced immunostaining of F4/80 (Figures 3c and d).

Owing to the high regenerative capacity of the liver, even when some fractions of hepatocytes undergo cell death in response to a carcinogenic dose of DEN or CCl₄, the remaining surviving hepatocytes should undergo a compensatory proliferative response. Immunostaining of proliferating cell nuclear antigen (PCNA) displayed higher numbers of proliferating hepatocytes in gankyrin<sub>hep</sub> mice than in the controls after CCl₄ exposure (Figure 3e). Accordingly, microarray assay revealed significant upregulation or downregulation of a large majority of cell cycle genes in gankyrin<sub>hep</sub> mice (data not shown), indicating that gankyrin further promoted hepatic compensatory proliferation after CCl₄ treatment.

**Gankyrin enhances CCl₄-mediated acute hepatocellular death via increasing JNK activity.** We further determined an involvement of liver cell death in the process of gankyrin-directed hepatic injury. As shown in Supplementary Figures S5A and B, gankyrin<sub>hep</sub> mice had grave hepatocellular damage owing to elevation of serum ALT and AST within 48 h after CCl₄ treatment for 2 weeks, and more extensive aberrant architecture and necrotic cells. Immunoblotting showed more cleaved PARP, caspase-3 and cytochrome c in gankyrin<sub>hep</sub> mice after CCl₄ treatment (Supplementary Figure SSC). Accordingly, TUNEL assays revealed severe hepatocyte apoptosis in CCl₄-treated gankyrin<sub>hep</sub> mice relative to similarly treated control mice (Supplementary Figure SSD). Taken together, it indicated that hepatic gankyrin promotes CCl₄-mediated hepatocyte death, which possibly resulted in subsequent fibrosis and tumor formation.

To explore the molecular mechanism underlying the enhanced liver injury and tumorigenesis in gankyrin<sub>hep</sub> mice, we detected several typical pathways involved in carcinogenesis. Although CCl₄ induced AKT, ERK and p38/MAPK activation, no differences were found between gankyrin<sub>hep</sub> mice and control littermates (Supplementary Figure S6). Phospho-JNK, a major contributor to acute liver failure and hepatocarcinogenesis, was observed to be constantly increased in the gankyrin group after CCl₄ treatment. By contrast, it transiently elevated to the top within 12 h but lowered then in the control group (Figure 4a; Supplementary Figure S7). Moreover, enhanced phospho-JNK activity was detected in the primary hepatocytes isolated from 4-week CCl₄-treated gankyrin<sub>hep</sub> mice (Figure 4b) or in the liver tumors from DEN plus CCl₄-treated gankyrin<sub>hep</sub> mice (Figure 4c). Thus, it suggests that persistent JNK activation most likely contributes to gankyrin-induced liver injury and tumorigenesis after CCl₄ exposure.

**Gankyrin enhanced JNK activation via the Rac1 pathway.** Small GTPases including RhoA, Rac1 and Cdc42 are able to trigger MAPK signaling leading to apoptosis in various cells. Rac1 activation has been reported to induce apoptosis through activating the JNK pathway. In the present study, CCl₄ treatment for different time points resulted in further elevation and persistence of Rac1 activity in gankyrin<sub>hep</sub> mice, whereas a relatively weak and transient rise was observed in the littermate group (Figure 5a; Supplementary Figure S8A). Moreover, increased Rac1 activity was also detected in the primary hepatocytes of the 4-week CCl₄-treated gankyrin<sub>hep</sub> group (Figure 5b). Consistently, DEN+CCl₄-treated gankyrin<sub>hep</sub> group also displayed higher Rac1 activity than littermate control did (Figure 5c).
Figure 2  Overexpression of gankyrin causes more evident liver fibrosis and HSC activation upon chronic CCl4 challenges. (a) Mice were treated with CCl4 for 2, 4 and 8 weeks (n=6). TGF-β1, collagen-1 and TIMP1 mRNA expression were analyzed by real-time PCR, normalized to β-actin. (b) Immunostaining of α-SMA in the liver sections from a and quantifications. (c) Representative immunofluorescence staining of liver sections from a with combinations of desmin and DAPI, quantified by counting positive cells in 10 high-power fields. (d) Western blot assay for expression of α-SMA. Data are represented as mean ± S.D. *P<0.05; **P<0.01. Scale bar, 100 μm.
RhoGDI directly interacts with Rac1 as a cytosolic inhibitor.\textsuperscript{21} Here, through coimmunoprecipitation in liver tissues from gankyrin hep or littermate control, the association of RhoGDI1 with Rac1 decreased gradually within 48-h CCl\textsubscript{4} administration, but their interaction was not altered by gankyrin (Supplementary Figure S8B). Thus, it indicated no effect of gankyrin on interaction between RhoGDI1 and Rac1.

Gankyrin has been reported to activate Rac1 through the RhoA/ROCK pathway.\textsuperscript{22,23} To explore the possibility of RhoA/ROCK involved in gankyrin-mediated Rac1 activation, we then examined the RhoA and ROCK activity in both groups. As displayed in Figure 5d, RhoA and ROCK activities markedly decreased after CCl\textsubscript{4} treatment, and further lowered in the gankyrin\textsuperscript{hep} group. Because of RhoGDI as a pivotal inhibitor of RhoA,\textsuperscript{24} we next investigated the effect of gankyrin on RhoGDI1 inhibition on RhoA. Immunoprecipitation showed a more enhanced connection between RhoGDI1 and RhoA in gankyrin\textsuperscript{hep} mice than that in littermate ones (Figure 5e). Collectively, it suggested that gankyrin promoted the interaction between RhoGDI and RhoA and inhibited RhoA/ROCK activity, leading to increased Rac1 activity.

To further confirm the involvement of Rac1 activity in gankyrin-mediated JNK activation, two small-molecule inhibitors for Rac1, NSC23766 or EHop-016, were used. As shown in Figure 6f, treatment with NSC23766 or EHop-016 reduced Rac1 activity in vivo after CCl\textsubscript{4} administration. Phospho-JNK levels in the gankyrin\textsuperscript{hep} group declined much more closely to that in controls (Figure 5f), directing that gankyrin sustained and enhanced JNK activity via the Rac1 pathway in this model.

JNK or Rac1 inhibitors ameliorated gankyrin-mediated liver fibrosis and blocked carcinogenesis after CCl\textsubscript{4} exposure. As gankyrin\textsuperscript{hep} mice displayed persistent Rac1/JNK activation during CCl\textsubscript{4} handling, it seems likely to account for the elevated susceptibility of gankyrin\textsuperscript{hep} mice to CCl\textsubscript{4}-induced liver fibrosis and hepatocarcinogenesis. To test this possibility, we treated both groups with 4-week CCl\textsubscript{4} in the presence or absence of specific JNK or Rac1 inhibitors.
Gankyrin promotes liver fibrosis transformation

X Zhao et al

Figure 4 Gankyrin promotes acute CCl4-induced liver cell death via sustained JNK activation. (a) Western blot analysis of p-JNK and total JNK in 4-week and 8-week CCl4-treated mouse liver. (b) Primary hepatocytes isolated from olive oil or 4-week CCl4-treated control littersmates or gankyrinhep mice were subjected to western blot analysis. (c) Western blot analysis of p-JNK in the livers of DEN+CCl4-treated mice

SP600125 or NSC23766, respectively. First, CCl4-mediated hepatocyte apoptosis in gankyrinhep mice was improved by SP600125 or NSC23766, evidenced by decreased cleavage of PARP and caspase-3 (Figure 6a). Moreover, both the liver fibrosis masses and inflammation degrees in gankyrinhep mice after CCl4 treatment were obviously ameliorated to that in control mice (Figures 6b and c). Correspondingly, after SP600125 treatment for 3 months, 16 weeks of CCl4-treated liver cancers in gankyrinhep mice was completely blocked, and liver cirrhosis was improved as well (Figure 6d). Meanwhile, elevated serum AST and ALT in gankyrinhep mice was reversed by the SP600125 treatment. In addition, the augmented inflammation and hepatocellular proliferation in the gankyrinhep group after 16-week CCl4 treatment were also restricted significantly by SP600125 (Supplementary Figures S10A and B). Taken together, it implied that Rac1/JNK activation accounts for gankyrin-mediated liver carcinogenesis in mice after CCl4 treatment.

Discussion

HCC carcinogenesis is a complex process involving various etiologic factors, dysregulations of several signal pathways, as well as genetic alterations, and it ultimately results in malignant transformation and HCC progression.25,26

To date, many investigations have focused on the possible mechanisms involved in liver tumorigenesis. However, mediators that are responsible for the high risk to develop HCC in the chronically injured liver are largely unknown.

One of the key features of gankyrin as an oncogene is its dysregulation of the balance of proliferation and apoptosis. However, its role in carcinogenesis in vivo remains unclear. Given that gankyrin increased in patients with cirrhosis, or at earlier stages of DEN-induced HCC formation in a rat model, it very likely induces hepatocarcinogenesis. In our study, we did not find any difference of tumor formation between the two groups under a single DEN treatment (Supplementary Figure S2), consistent with Fujita recent reports.27 However, DEN plus CCl4 treatment resulted in development of cirrhosis and tumor is entirely skipped. In contrast, the model of a combination of DEN and CCl4 incorporates chronic injury, inflammation, fibrogenesis and thus faithfully recapitulates human HCC development. Thus, the oncogenic function of gankyrin mostly relied on persistent hepatocyte damage and inflammatory microenvironment.

Chronic inflammation is a critical contributor to carcinogenesis, including HCC, colon cancer and lung cancer.28–30 CCl4 administration produces the reactive metabolite trichloromethyl radical via cytochrome P450, and it causes hepato-cellular injury and necrosis by eliciting the production of reactive oxygen intermediates and by peroxidative degradation of membrane phospholipids.31 Repeated administration of CCl4 for a prolonged period of over 2 years induces 50% HCC in mice.32,33 Intriguingly, after a single prolonged injection of CCl4 for 16 weeks, satellite nodules appeared only on the livers of gankyrinhep mice. Moreover, tumors developing by this regimen showed typical features of HCC. In contrast, under the same treatment, the littersmate control only underwent the development of cirrhosis but not malignant transformation. In addition to cell death, more proliferation of hepatocytes in gankyrinhep mice after CCl4 stimulation further confirmed the synergistic effect of gankyrin on compensatory proliferation of hepatocytes. Given its promotion of cell survival, it seems contradictory for gankyrin augmenting CCl4-induced hepatocyte deaths, which triggered more compensatory proliferative response in the parenchyma leading to enhanced tumor formation. However, the differences between in vitro and in vivo might be explained by the inflammatory component in experimental animal models. As compensatory proliferation is critical for tumor promotion, the most possible interpretation of our results is that, in hepatocytes, gankyrin promotes malignant transformation of liver cirrhosis by enhancing compensatory growth under inflammatory microenvironment.

Our previous studies demonstrated that gankyrin activates AKT signaling to promote HCC invasion and metastasis.11 However, no obvious phospho-AKT was observed in gankyrinhep mice or in littermate control even after CCl4 exposure (Supplementary Figure S6A). Given the inhibitory effect of gankyrin on NF-κB activity via nuclear export of RelA, we herein also observed fewer cells with nuclear localization of RelA in the gankyrinhep group regardless of no impression on...
NF-κB downstream genes relating to apoptosis, indicating that NF-κB is probably dispensable for gankyrin-mediated hepatocarcinogenesis in the CCl₄ model (Supplementary Figures S9A and B). Considering that gankyrin can regulate p53, Rb and CDK4 signals, related molecules were compared at the protein level, including p53 and its downstream targets Bax and p21, phospho-RB and CDK4 (Supplementary Figure S9C). However, almost no difference was found between the gankyrinhep and control mice, indicating that these pathways are not involved. Moreover, no difference of Oct4 expression was found between the two groups after CCl₄ administration for 8 weeks (Supplementary Figure S9D). It seems contradictory to our preceding report that gankyrin expands liver tumor-initiator cells via Oct4. To our knowledge, one possible reason is that HSCs have a pivotal role to orchestrate parenchymal and nonparenchymal cells, rather than progenitor cells, involving this process. Of course, more details need to be determined in the future.

The JNK pathway has been implicated in regulating cellular stress response, apoptosis, malignant transformation and HCC carcinogenesis. JNK activation for a long time will trigger apoptosis in some cell types. Here, after DEN plus CCl₄ or single CCl₄ stimulation, persistent JNK activation displayed in liver tissues or in primary hepatocytes from gankyrinhep mice, accompanied by increased apoptosis of liver cells. Small GTPase Rac1 is able to activate JNK to influence apoptotic cell death. In our present study, overexpression of gankyrin increased CCl₄-induced Rac1 activity relying on RhoA, another member of the Rho GTPase family.

It has been reported that RhoA/ROCK inhibits the Rac pathway and gankyrin activates Rac through the RhoA/ROCK pathway. Consistently, RhoA/ROCK activity decreased, whereas the interaction between RhoGDI and RhoA increased in gankyrinhep mice. Our postulation is that gankyrin enhances the association between RhoGDI and RhoA, inhibits RhoA activity and then indirectly activates the Rac/JNK signals. In addition, specific Rac inhibitors significantly blocked gankyrin-mediated JNK activation. Combined with impediment of gankyrin-mediated hepatic fibrosis and HCC formation by Rac or JNK inhibitor, Rac1 is very likely involved in gankyrin-induced JNK activation.

A procarcinogenic effect for JNK in the liver especially in nonparenchymal cells has been demonstrated, whereas its tumor suppressor role in hepatocytes has also been reported. The effect of gankyrin on JNK activity in nonparenchymal cells needs to be further explored in the future. Cirrhosis is the most common and unifying condition associated with hepatocarcinogenesis, with almost 90% of HCC cases arising in the setting of established cirrhosis, which develops after long latencies (20–40 years) of chronic liver disease. At present, a range of primary treatment options including antiviral therapy and weight reduction strategies are variably effective in these conditions.
Unfortunately, a significant number of patients still progress to end-stage liver disease and many require orthotopic liver transplantation. Thus, it is urgently required for developing new therapeutic strategies for the prevention or treatment of hepatic fibrosis, cirrhosis and HCC. Our results demonstrate the significance of Rac1/JNK in cirrhosis or HCC and the potential utilization of Rac1/JNK targeting for liver diseases therapy. Recently, a new strategy targeting multiple kinases was proposed for cancer treatment. Our previous findings have shown that targeting gankyrin significantly blocked tumor-initiating cell-mediated tumor cell expansion and metastasis. In light of our studies, a combination of gankyrin and Rac1/JNK targeting may profoundly improve liver cirrhosis therapies.

Materials and Methods

Human tissue specimen. HCC tissue samples were obtained from surgical resections of liver tumors with informed consent of the patients at the Eastern Hepatobiliary Surgery Hospital (Shanghai, China). Cirrhosis tissues were obtained from patients after liver transplantation at Zhongshan Hospital, Fudan University (Shanghai, China). All human sample collection procedures were approved by the China Ethical Review Committee.

Transgenic mice. Gankyrin\textsuperscript{Rep} transgenic mice were generated as follows. A full-length cDNA of human gankyrin, followed by myc-tag and His-tag, was ligated into the pL253 vector after the 12.5-kb albumin promoter. The 13.6-kb whole-insert fragment was excised by SacI and injected into fertilized eggs. Mice were maintained on a C57BL/6 J background. Animals were housed on a standard rodent chow diet with 12-h light-dark cycle. Offspring were genotyped using the following primers: gankyrin forward 5\'-AGCGAGTCTTTCTGCACACA-3\', gankyrin reverse 5\'-ACAGCATTACCTTGAGCACC-3\'. All the experiments were carried out on two different transgenic lines.

DEN or DEN+CCl\textsubscript{4}-induced liver cancer model. All animals received human care according to the criteria outlined in the ‘Guide for the Care and Use of Laboratory Animals’ prepared by the National Academy of Sciences and published by the NIH (publication 86-23 revised 1985). The DEN-induced liver cancer model was established as described previously. DEN+CCl\textsubscript{4}-induced liver tumor was described in the reports of Diane H Dapito. For gankyrin\textsuperscript{Rep} mice and wild-type controls, HCC was induced by the combination of DEN (25 mg/kg i.p.) given at day 15 postpartum and weekly injections of CCl\textsubscript{4} (5 ml/kg i.p., 10% dissolved in olive oil) for different time.

CCl\textsubscript{4}-induced liver injury, fibrosis and tumor formation. Four-to-six-week-old male gankyrin\textsuperscript{Rep} mice and their wild-type littermates were injected with CCl\textsubscript{4} (4 ml/kg i.p., 5% dissolved in olive oil) three times a week for up to 16 weeks. The mice were killed at different time points after the last injection of CCl\textsubscript{4} and liver tissues were harvested for experiments.

Inhibitor treatment. Specific JNK inhibitor, SP600125 (Selleck Chemicals, Houston, TX, USA), was injected at a dose of 1 mg/kg/day i.p. for 2 weeks or 1 mg/kg...
Gankyrin promotes liver fibrosis transformation
X Zhao et al.

Acknowledgements. We thank Professor Jia Fan and Jian Zhou (Zhongsan Hospital, Fudan University) for kindly sharing the human liver cirrhosis tissues. This work was supported by the projects from the National Natural Science Foundation of China (81372206, 81101714, 91029732 and 91122901), the State Key Project for Infectious Diseases (2012ZX10002-030) and 2013ZX10002010-002).

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860–867.

2. E-Senag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557–2576.

3. Brix J, Shermar M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208–1236.

4. Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010; 7: 43–53.

5. Park TJ, Kim HS, Byun KH, Jung J, Lee YS, Lim IK. Sequential changes in hepatocarcinogenesis induced by diethylnitrosamine plus thioacetamide in Fischer 344 rats: induction of gankyrin expression in liver fibrosis, pRB degradation in cirrhosis, and methylation of p16(Ink4A) exon 1 in hepatocellular carcinoma. Mol Carcinog 2001; 30: 39–50.

6. Fu X, Tan L, Liu S, Li H, Chen L, Qin J et al. A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics. J Cancer Res Clin Oncol 2004; 130: 514–520.

7. Higashitani H, Higashitani H, Itoh K, Sakurai T, Nagao T, Sumimoto H et al. The oncprotein gankyrin binds to MDM2/HEM2, enhancing ubiquitination and degradation of p53. Cancer Cell 2005; 8: 75–87.

8. Higashitani H, Itoh K, Nagao T, Dawson S, Nonoguchi K, Kid T et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med 2005; 6: 96–100.

9. Qian YW, Chen Y, Wang Y, Fu J, Cao J, Ren YB et al. p28(GANK) prevents degradation of Oct4 and promotes expansion of tumour-initiating cells in hepatocarcinogenesis. Gastroenterology 2012; 142: 1547–1558.e14.

10. Chen Y, Li HH, Fu J, Wang XF, Ren YB, Dong LW et al. Oncoprotein p28 GANK binds to ReA and retains NF-kappab in the cytoplasm through nuclear export. Cell Res 2007; 17: 1020–1029.

11. Fu J, Chen Y, Cao J, Luo T, Qian YW, Yang W et al. p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hippoxia-inducible factor-1alpha pathways. Hepatology 2011; 53: 181–192.

12. Sun W, Ding J, Wu K, Ning BF, Wen W, Sun HY et al. Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells. Hepatology 2011; 54: 1259–1272.

13. Sun W. Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of hepatocytes and hepatoma cells. Hepatology 2011; 54: 1259–1272.

14. Hui J, Zafouka K, Scheuch H, Stepien E, Wang EF. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest 2008; 118: 3943–3953.

15. Das M, Garlick DS, Greiner DL, Davis RJ. The role of JNK in the development of hepatocellular carcinoma. Genes Dev 2011; 25: 634–645.

16. Schwabe EF, Brenner DA. Mechanisms of liver injury. J. NatF-alpha-induced liver injury: role of IFK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 2006; 290: G583–G589.

17. Subauste MC, Von Herrath M, Benard V, Chamberlain CE, Chuang TH, Chu K et al. RAF family proteins modulate rapid apoptosis induced by cytokotic T lymphocytes and Fas. J Biol Chem 2007; 282: 9725–9733.

18. Chuang TH, Hahn KM, Lee JD, Danley DE, Bokoch GM. The small GTPase Cdc42 initiates an apoptotic signaling pathway in Jurkat T lymphocytes. Mol Biol Cell 1997; 8: 1687–1698.

19. Jin S, Ray RM, Johnson LR. Rac1 mediates intestinal epithelial cell apoptosis via JNK. Am J Physiol Gastrointest Liver Physiol 2006; 291: G1137–G1147.

20. Jin S, Ray RM, Johnson LR. NF-alpha/cyclooxygenase-induced apoptosis in intestinal epithelial cells requires Rac1-regulated reactive oxygen species. Am J Physiol Gastrointest Liver Physiol 2006; 290: G308–G317.

21. Choy Y, Huh KH, Park YJ, Do JH, Joo DJ, Kim MS et al. Cellular function of RhoGDI-alpha mediates the cycling of Rac1 and the regulation of pancreatic beta cell death. Transplant Proc 2012; 44: 1083–1085.

22. Zhen C, Chen L, Zhao Q, Liang B, Gu YX, Bai ZF et al. Gankyrin promotes breast cancer cell metastasis by regulating Rac1 activity. Am J Pathol 2013; 182: 1811–1822.

23. Arai T, Sato T, Ohtani S, Inoue T, Hara T et al. Gankyrin expression as a novel marker of apoptosis and cell death in mouse hepatocytes. Apoptosis 2013; 18: 133–143.

24. Jiang D, Jiang H, Liao J, Chen J, Zhang J, Pan X et al. Gankyrin promotes liver fibrosis transformation. Cancer Lett 2014; 346: 17–23.

25. Liu Y, Higashitani H, Itoh K, Sakurai T, Komie K, Hirotta K et al. Overexpression of gankyrin in mouse hepatocytes induces hemangiosarcoma by suppressing factor inhibiting hypoxia-inducible factor-1alpha.
factor-1 (FIH-1) and activating hypoxia-inducible factor-1. Biochim Biophys Res Commun 2013; 432: 22–27.

28. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amt S, Kasem S et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461–466.

29. Sohal SS, Ward C, Danial W, Wood-Baker R, Walters EH. Recent advances in understanding inflammation and remodeling in the airways in chronic obstructive pulmonary disease. Expert Rev Respir Med 2013; 7: 275–288.

30. Sun B, Karin M. The therapeutic value of targeting inflammation in gastrointestinal cancers. Trends Pharmacol Sci 2014; 35: 349–357.

31. McCay PB, Lai EK, Poyer JL, DuBose CM, Janzen EG. Oxygen- and carbon-centered free radical formation during carbon tetrachloride metabolism. Observation of lipid radicals in vivo and in vitro. J Biol Chem 1984; 259: 2135–2143.

32. Fausto N, Campbell JS. Mouse models of hepatocellular carcinoma. Semin Liver Dis 2010; 30: 87–98.

33. Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM. Experimental models of hepatocellular carcinoma. J Hepatol 2008; 48: 859–879.

34. Minden A, Karin M. Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta 1997; 1333: F85–F104.

35. Kluwe J, Pradere JP, Gwak GY, Mencin A, De Minicis S, Österreicher CH et al. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 2010; 138: 347–359.

36. Liu J, Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res 2005; 15: 36–42.

37. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Cell Biol 2007; 19: 142–149.

38. Hochsedlinger K, Wagner EF, Sabapathy K. Differential effects of JNK1 and JNK2 on signal specific induction of apoptosis. Oncogene 2002; 21: 2441–2445.

39. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239–252.

40. Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, Sarin SK. From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer 2013; 2: 367–383.

41. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–390.

42. Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005; 41: 307–314.

43. McCarty MF. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Cancer Ther 2004; 3: 349–350.

44. Yu LX, Yan HX, Liu Q, Yang W, Wu HP, Dong W et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 2010; 52: 1322–1333.

45. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012; 21: 504–516.

46. Sun H, Chen L, Zhou W, Hu L, Li L, Tu Q et al. The protective role of hydrogen-rich saline in experimental liver injury in mice. J Hepatol 2011; 54: 471–480.

47. Yan HX, Wu HP, Zhang HL, Ashton C, Tong G, Wu H et al. p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release. J Hepatol 2013; 59: 762–768.

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)